Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177


Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.

Hilliard P, Zourikian N, Blanchette V, Chan A, Elliott B, Israels SJ, Nilson J, Poon MC, Laferriere N, Van Neste C, Jarock C, Wu J, McLimont M, Feldman B.

J Thromb Haemost. 2013 Mar;11(3):460-6. doi: 10.1111/jth.12113.


Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.

Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group.

J Thromb Haemost. 2006 Jun;4(6):1228-36.


Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.

Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L.

J Thromb Haemost. 2010 Jan;8(1):83-9. doi: 10.1111/j.1538-7836.2009.03650.x. Epub 2009 Oct 11.


Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.

J Thromb Haemost. 2015 Jun;13(6):967-77. doi: 10.1111/jth.12911. Epub 2015 Apr 23.


Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.

Schobess R, Kurnik K, Friedrichs F, Halimeh S, Krümpel A, Bidlingmaier C, Nowak-Göttl U.

Thromb Haemost. 2008 Jan;99(1):71-6. doi: 10.1160/TH07-06-0417.


Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.

Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM.

Haemophilia. 2008 Jul;14(4):743-52. doi: 10.1111/j.1365-2516.2008.01664.x. Epub 2008 Apr 16.


Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL.

N Engl J Med. 2007 Aug 9;357(6):535-44.


Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada.

Kraft J, Blanchette V, Babyn P, Feldman B, Cloutier S, Israels S, Pai M, Rivard GE, Gomer S, McLimont M, Moineddin R, Doria AS.

J Thromb Haemost. 2012 Dec;10(12):2494-502. doi: 10.1111/jth.12025.


To bleed or not to bleed - is that a question?

Aledort LM.

J Thromb Haemost. 2010 Jan;8(1):81-2. doi: 10.1111/j.1538-7836.2009.03668.x. Epub 2009 Oct 24. No abstract available.


Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.

Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM.

J Thromb Haemost. 2010 Feb;8(2):269-75. doi: 10.1111/j.1538-7836.2009.03703.x. Epub 2009 Nov 23.


A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.

Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY; Prophylaxis Study Group.

J Thromb Haemost. 2012 Mar;10(3):359-67. doi: 10.1111/j.1538-7836.2011.04611.x.


Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.

J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10.


Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).

Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M; LEOPOLD II Study Investigators.

J Thromb Haemost. 2015 Mar;13(3):360-9.


Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.

Tagliaferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrera DB, Gagliano F, Zanon E, Mancuso ME, Valdré L, Mameli L, Amoresano S, Mathew P, Coppola A; POTTER Study Group.

Thromb Haemost. 2015 Jul;114(1):35-45. doi: 10.1160/TH14-05-0407. Epub 2015 Apr 9.


Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.

den Uijl IE, Fischer K.

Thromb Haemost. 2008 May;99(5):965; author reply 966-8. doi: 10.1160/TH08-02-0097. No abstract available.


[Analysis of individualized primary prophylactic treatment of 19 cases of children with severe hemophilia A].

Liu GQ, Tang L, Wu XY, Zhen YZ, Li G, Chen ZP, Wang Y, Zhang NN, Zhang JS, Yu GX, Wu RH.

Zhonghua Er Ke Za Zhi. 2016 Dec 2;54(12):923-926. doi: 10.3760/cma.j.issn.0578-1310.2016.12.010. Chinese.


Prevention of arthropathy in haemophilia: prophylaxis.

Santagostino E, Mancuso ME.

Haemophilia. 2008 Nov;14 Suppl 6:16-9. doi: 10.1111/j.1365-2516.2008.01884.x.


Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Fischer K, Steen Carlsson K, Petrini P, Holmström M, Ljung R, van den Berg HM, Berntorp E.

Blood. 2013 Aug 15;122(7):1129-36. doi: 10.1182/blood-2012-12-470898. Epub 2013 Jun 18.

Supplemental Content

Support Center